News

News

09-11

2025

Sciwind Biosciences to Present Phase III Data on Ecnoglutide Injection at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD)

08-23

2025

Sciwind Biosciences Published T2DM Phase III EECOH-2 Trial Results of Ecnoglutide in Lancet Diabetes & Endocrinology

06-21

2025

Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology and Oral Presentation at ADA Scientific Sessions

06-12

2025

Sciwind Biosciences to Present Phase 3 Clinical Data on Ecnoglutide (GLP-1 analog) for Obesity and Type 2 Diabetes, and Preclinical Data on Novel Urocortin 2 Analog at ADA2025

01-10

2025

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio

12-12

2024

Sciwind’s Second Marketing Authorization Application of Ecnoglutide for Chronic Weight Management Has Been Accepted by the NMPA of China

<
1
2
3
4
5
>